Curis, Debiopharm Start Phase I Study Of Debio 0932 With Everolimus NASDAQ (RTTNews.com) - Curis, Inc.( CRIS ), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combination with everolimus, an inhibitor of mammalian target of rapamycin, ... CURIS, INC. : Curis and Debiopharm Group(TM) Announce Initiation of Phase I ... |
